TrialPath

Find a study

Match me to a study

239 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicMental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

149 studies on the map

Study of ALTO-300 in MDD — Site 200, PhoenixZelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder — University of Alabama at Birmingham, BirminghamPragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults — University of Alabama at Birmingham, BirminghamA Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend) — Lighthouse Psychiatry, GilbertA Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure — Research Site, FairhopeEASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) — Apogee Clinical Research, HuntsvilleA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria — Phoenix Children's Hospital | Main - Transplant Department, PhoenixA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) — University of Alabama at Birmingham, BirminghamA Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria — Phoenix Children's Hospital | Main - Transplant Department, PhoenixA Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA) — Noble Clinical Research, TucsonA Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease — Research Site, DecaturStudy of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder — University of Alabama at Birmingham, Huntsville"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" — Scottsdale Research Institute, PhoenixA Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder — Harmonex /ID# 277517, DothanA Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor — Neurocrine Clinical Site, BryantMulticenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients — Harmonex Neuroscience Research, DothanA Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder — IMA Clinical Research Phoenix, PhoenixA Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder — UAB Psychiatry and Behavioral Neurology, BirminghamA Study of Brenipatide in Adult Participants With Major Depressive Disorder — Accellacare - Moorpark, MoorparkA Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) — Harmonex Neuroscience Research, DothanALTO-207 in Adults With Treatment-resistant Depression (TRD) — Site 7074, BirminghamPramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV — Alabama CRS, BirminghamLong-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, HuntsvilleA Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms — Clinical Research Site, BellflowerStudy to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease — Apogee Clinical Research, LLC, HuntsvilleA Study to Evaluate the Effectiveness of DT-101 in Patients With Depression — Draig Clinical Site, BentonvilleA Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder — NoesisPharma, LLC, PhoenixA Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia — R1 Therapeutics Clinical Trial Site, HuntsvilleA Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) — Noble Clinical Research, TucsonALTO-100 in Bipolar Disorder With Depression (BD-D) — Site 6036, ChandlerA Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. — Research Site, SurpriseEvaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder — Vanda Investigational Site, PhoenixACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response — University of Alabama at Birmingham, BirminghamA Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease — N America Res Inst - San Dimas, San DimasA Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China — Renal Consultants Medical Group, Granada HillsA Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) — Seaport Investigator Site, ChinoFerric Citrate and Chronic Kidney Disease in Children — University of California, Los Angeles, Los AngelesSotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease — Stanford University Medical Center, StanfordA Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, OceansideProact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease — Nephrology Consultants, HuntsvilleA Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis — Childrens Hospital of Los Angeles, Los AngelesEmpagliflozin Treatment in Kidney Transplant Recipients — Edward Hines Jr. VA Hospital, Hines, IL, HinesA Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder — CI Trials, BellflowerPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms — University of Alabama at Birmingham, BirminghamA Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. — Pillar Clinical Research /ID# 226504, BentonvilleNBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, ChinoStudy to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, Little RockClinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol — Clinical Research Site, ChinoSAfety of Regional Citrate Anticoagulation (SARCA Study) — John L. McClellan Memorial Veterans' Hospital, Little RockNBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, HuntsvilleCSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes — VA Long Beach Healthcare System, Long Beach, CA, Long BeachA Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors — Site 108, ChandlerMaridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity — University of Alabama Saint Vincent's Birmingham, BirminghamEASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Pinnacle Research Group, LLC, AnnistonA Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder — University of Alabama at Birmingham, BirminghamA Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD) — Memorial Healthcare System, HollywoodEvaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity — Alliance For Multispecialty Research - Daphne, DaphneOpen-label Extension Study of Zigakibart in Adults With IgA Nephropathy. — Colorado Kidney Care Nephrology, DenverA Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) — Mayo Clinic in Arizona, ScottsdalePCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study — Mood Institute, MilfordA Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity — Advanced Cardiovascular, LLC, Alexander CitySafety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD — Clinical Trial Site, San FranciscoShingrix in Renal Transplant Recipients — University of Colorado Anschutz, AuroraCombined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) — Nephrology of North Alabama, DecaturE-Mindfulness Approaches for Living After Breast Cancer — Mayo Clinic Hospital in Arizona, PhoenixREgulatory T Cell Therapy to Achieve Immunosuppression REduction — Mayo Clinic in Arizona, PhoenixStudy of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma — Stanford, Palo AltoCombination of Novel Therapies for CKD Comorbid Depression — Stony Brook University Medical Center, Stony BrookStudy of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders — National Institutes of Health Clinical Center, BethesdaModulating Exercise Dosage to Improve Concussion Recovery — University of Colorado Denver, AuroraSit Less, Interact and Move More (SLIMM) 2 Study — Stanford University, StanfordNAVIGATE Kidney: A Multi-level Intervention to Reduce Kidney Health Disparities — Denver Health and Hospital Authority, DenverOral Iron in Children With Chronic Kidney Disease — Weill Cornell Medicine / New York Presbyterian Hospital, New YorkSodium Bicarbonate and Mitochondrial Energetics in Persons With CKD — University of California Davis Health, SacramentoSafety and Efficacy of Empagliflozin in Hemodialysis — Brigham and Women's Hospital, BostonCoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease — University of California Davis Health, SacramentoStudy to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD — Northwestern Memorial Hospital, ChicagoBone in CKD Alkali Response (BICARb Pilot Trial) — Albert Einstein College of Medicine, The BronxBiomarker-guided rTMS for Treatment Resistant Depression — Stanford University, StanfordPramipexole to Enhance Social Connections — University of California, San Diego, San DiegoACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression — Stanford Psychiatry and Behavioral Sciences Department, Palo AltoSearch for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness — Acacia Clinics, SunnyvaleStudy of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY) — Autobahn Site #131, BirminghamA Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD) — IMA Clinical Research- Phoenix, PhoenixSafety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant — University of Cincinnati, CincinnatiMechanisms of Semaglutide Therapy in Heart Failure Patients — Greenstone Biosciences, Palo AltoNeurovascular Transduction During Exercise in Chronic Kidney Disease — Emory University Hospital Midtown, AtlantaPioglitazone to Reduce Sympathetic Overactivity in CKD Patients — University of Texas at Arlington, ArlingtonA Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With AION-301 Administered by Intravenous Infusion Compared With Placebo Administered by Intravenous Infusion Investigational Intervention in Participants Aged 35 to 75 Years of Age With Chronic Kidney Disease (CKD) — SouthCoast Research Center, Inc., MiamiNeurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD — Emory Clinic, AtlantaKetamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients — Texas Tech University Health Sciences Center Lubbock, LubbockAβ Dynamics in LLMD — NYU Langone Health, New YorkSubanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients — Mayo Clinic, JacksonvilleInflammation and Depression in People With HIV — Grady Memorial Hospital, AtlantaBuspirone and Melatonin for Depression Following Traumatic Brain Injury — Massachusetts General Hospital, BostonA Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression — Draig Clinical Site, DeSotoPRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis — University of Alabama at Birmingham, BirminghamPioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants — Texas Diabetes Institute/UH, San AntonioSympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study) — University of Kansas Medical Center, Kansas CityGlucagon-Like Peptide-1 Receptor Agonist in ADPKD — University of Colorado - Anschutz Medical Campus, AuroraUric Acid Lowering Trial in Youth Onset T2D — Children's Hospital Colorado, AuroraEffects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults — University of Texas Health Science Center at San Antonio, San AntonioEffect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT — Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute), TorranceMechanism of SGLT2 Inhibition in the Kidney — University of Michigan, Ann ArborImproving Coronary Vascular Health in Women — Massachusetts General Hospital, BostonNAD Augmentation in Diabetes Kidney Disease — Brigham and Women's Hospital, BostonPatient-driven Management of BP in CKD — Iowa City VA Health Care System, Iowa City, IA, Iowa CityBreakthrough - T1DM and Chronic Kidney Disease — The University of Chicago, ChicagoTestosterone Treatment in Men With Chronic Kidney Disease — Saint Louis Univeristy, St LouisImpact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile — Deepa Valvi, LexingtonStudy to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD — New York University Langone Health, New YorkEquol and Vascular Function in Women With Chronic Kidney Disease — University of Colorado Anschutz Medical Campus, AuroraErtugliflozin in Chronic Heart Failure — Yale School of Medicine, New HavenSafety of Short-course of NSAIDs in Pediatric Patients With CKD — Children's Hospital Colorado, AuroraAnti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine — Brigham and Women's Hospital, BostonEffect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease — Northwestern University, ChicagoEffect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD — Washington DC Veterans Affairs Medical Center (688), Washington D.C.Acute Equol Supplementation and Vascular Function in Women With and Without CKD — University of Colorado Anschutz Medical Campus, AuroraKetamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression — VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann ArborDetermining Optimal Treatment Sequences in Anxious Depression (DOTS-AD) — University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience, CincinnatiAcceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality — The University of Texas Health Science Center at Houston, HoustonIntravenous Ketamine for Treatment-Resistant Depression — Mayo Clinic in Rochester, RochesterAcceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease — Children's Hospital Los Angeles, Los AngelesBehavioral Activation Delivered Via Home-based Telehealth to Improve Functioning in Cardiovascular Disease Patients Recently Discharged From Inpatient Care — Ralph H. Johnson VA Medical Center, Charleston, SC, CharlestonLong-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression — Massachusetts General Hospital, BostonEstablishing Multimodal Brain Biomarkers for Treatment Selection in Depression — Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600, AustinKetamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression — Icahn School of Medicine at Mount Sinai, New YorkExamining the Effects of Estradiol on Neural and Molecular Response to Reward — University of North Carolina at Chapel Hill, Chapel HillInvestigation to Understand and Optimize Psilocybin — Vail Health Behavioral Health, EdwardsTRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors — The University of Texas M. D. Anderson Cancer Center, HoustonNeural Circuit Effects of Ketamine in Depression — Icahn School of Medicine at Mount Sinai, New YorkSleep Health in U.S. Marines — San Diego State University, San DiegoNeuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV — Massachusetts General Hospital, BostonLeucine in Midlife Depression — Emory University Hospital, AtlantaFamily Acceptance Project Online (Pilot RCT) — University of Michigan, Ann ArborCombination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer — MD Anderson Cancer Center, HoustonCannabis for Palliative Care in Cancer — Anschutz Health Sciences Building, AuroraPsilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer — Ohio State University Comprehensive Cancer Center, Columbus5-HTP and Creatine for Depression R33 Phase — University of Utah Department of Psychiatry, Salt Lake CityProcesses and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression — Laureate Institute for Brain Research, TulsaKetamine Alcohol (in Treatment-Resistant Depression) — University of Iowa Health Care, Iowa CityPET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine. — Stony Brook University: Dept of Psychiatry, Stony BrookModulating Spinal Interoceptive Pathways to Evaluate Their Role and Therapeutic Potential in MDD Symptomatic Domains — Lindner Center of Hope, MasonPersonalized Ultrasonic Brain Stimulation for Depression (R61) — University of Utah, Salt Lake CityNebulized Ketamine for the Treatment of Major Depressive Disorder — Maimonides Medical Center, BrooklynBezafibrateTreatment for Bipolar Depression: A Proof of Concept Study — The Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General Hospital, BostonA Digital Intervention for Post-Stroke Depression and Executive Dysfunction — Weill Cornell Medical Center, New YorkPsilocybin Therapy for Depression in Parkinson's Disease — University of California, San Francisco, San FranciscoA New Intervention to Improve Function in Veterans With Anxiety and Depression — Durham VA Medical Center, Durham, NC, Durham

Showing the 150 nearest — narrow your filters for fewer, closer studies.